NOTCH1 Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial.

doi:10.1200/JCO-24-01818

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

NOTCH1 Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Jun 2025

Lu Zhihao, Du Wenting, Jiao Xi, Wang Yanni, Shi Jingwen, Shi Yang, Shu Yongqian, Niu Zuoxing, Hara Hiroki, Wu Jun, Hsu Chih-Hung, Van Cutsem Eric, Brock Malcolm V, Zhang Zhang, Ding Ningning, Zhang Yun, Shen Zhirong, Shen Lin

Abstract excerpt

PURPOSE: Although multiple agents targeting PD-1 have been approved as second-line treatment for esophageal squamous cell carcinoma (ESCC), only a fraction of patients derive long-term survival. Hence, reliable predictive biomarkers are urgently needed. METHODS: Comprehensive tumor genomic profiling and transcriptome sequencing were performed on samples from the RATIONALE-302 study. We also conducted single-cell...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Esophageal Neoplasms

Share to Esophageal Squamous Cell Carcinoma

Share to Mice

Share to Mutation

Share to Receptor, Notch1

Share to Survival Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 40179324
DOI: 10.1200/JCO-24-01818
PMCID: PMC12118624

Genes

NOTCH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

NOTCH1 Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial.PMID 40179324Read ↗

An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma.Semantic proximity Read ↗

Tumor-immune microenvironment and NRF2 associate with clinical efficacy of PD-1 blockade combined with chemotherapy in lung squamous cell carcinoma.Semantic proximity Read ↗

Single-cell sequencing reveals immune features of treatment response to neoadjuvant immunochemotherapy in esophageal squamous cell carcinomaSemantic proximity Read ↗

Tumor Niche Network-Defined Subtypes Predict Immunotherapy Response of Esophageal Squamous Cell CancerSemantic proximity Read ↗

Single cell sequencing revealed the mechanism of PD-1 resistance affected by the expression profile of peripheral blood immune cells in ESCCSemantic proximity Read ↗

Identification of a novel signature based on T cell-related genes to explore prognosis and immune microenvironment in esophageal squamous carcinomaSemantic proximity Read ↗

Development of a Novel Prognostic Model for Esophageal Squamous Cell Carcinoma: Insights into Immune Cell Interactions and Drug SensitivitySemantic proximity Read ↗

Integrative analysis of T cell-mediated tumor killing-related genes reveals KIF11 as a novel therapeutic target in esophageal squamous cell carcinomaSemantic proximity Read ↗

Multi-region sequencing unveils novel actionable targets and spatial heterogeneity in esophageal squamous cell carcinomaSemantic proximity Read ↗

Prognostic value of genomic mutation signature associated with immune microenvironment in southern Chinese patients with esophageal squamous cell carcinoma.Semantic proximity Read ↗

siRNA Library Screening Identifies a Druggable Immune-Signature Driving Esophageal Adenocarcinoma Cell GrowthSemantic proximity Read ↗

Clinical prognostication and immunotherapy response prediction in esophageal squamous cell carcinoma using the DNA damage repair‐associated signatureSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.